Asia, Latin American, and Eastern Europe are increasingly attractive geographies in which to conduct clinical research.
Asia, Latin American, and Eastern Europe are increasingly attractive geographies in which to conduct clinical research. The data in GrantPlan® shows that overhead rates in many countries are increasing, as illustrated by China and India. According to www.ClinicalTrials.gov, GrantPlan subscribers conduct over 76 percent of all clinical trials.
Drug development professionals already know that successful investigators and sites often seek to command a premium in any discussion over clinical trial agreement negotiations. Similarly, when multiple studies in the same indication are looking to enlist investigators, individual sites are often in a stronger position to command a price premium. We see much the same phenomenon at work in geographies newer to clinical research. They offer large naïve patient pools, well trained physicians, and potentially lower costs.
Average institutional overhead rates in China and India.
For instance, recent data shows that China and India are experiencing sustained growth in the number of clinical sites involved in commercial clinical trial activity. Unlike in the United States, the vast majority of clinical research in China and India is done in hospitals, rather than private practice. The demand for clinical research services is growing in the institutions, while the supply is clearly limited.
Many of these institutions in China and India are putting in substantial effort to better understand their clinical trials' indirect costs. These are all the costs that are necessary to sustain the infrastructure for the conduct of clinical research, but which cannot be directly charged to any specific project. Supply and demand also helps to explain the increase in overhead rates. These institutions are in demand. Institutions can charge these rates because someone will pay them.
—TTC for more information, contact help@ttc-llc.com
Industry Assessment of Risk-Based Quality Management Emphasizes Value of Adoption
April 4th 2024A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.